Navigation Links
Texas State Tests Potential New Cancer-Fighting Weapon

SAN MARCOS, Texas, Oct. 12 /PRNewswire/ -- Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

Dhiraj Vattem, professor in the Department of Family and Consumer Sciences, and Reed Richardson, professor in the Department of Agriculture, supervised the tests in cooperation with Orizon Research. Results were announced at a University press conference.

The product, known as ALKA-V6, is a proprietary modified silicon-based compound developed by Orizon Research. The in-vitro evaluations will be followed by a second phase of testing for ALKA-V6 which will consist of end-point evaluations in in-vivo systems. Results from second-phase testing are expected within the next 12 months.

The anticancer studies revealed ALKA-V6:

  • prevented attachment of cancer cells
  • (a 1:40 dilution) completely killed all colon cancer cells (100% lethality)
  • reduced harmful mutations in the DNA
  • induced apoptosis (programmed cell death)
  • stimulated important antioxidant enzymes

The anti-retroviral studies revealed ALKA-V6:

  • increased nitric oxide dependent anti-viral effects
  • inhibited enzymes important in viral assembly, metabolism, and replication
  • caused changes in the surface carbohydrate composition and metabolism
  • inhibited the activity of the enzyme responsible for reverse transcription

The unique electrochemical and structural composition of ALKA-V6 indicates that it may provide an alternative basis for control of cancer cell growth and virus survival. However, this implication is based solely on in-vitro results and end-point in-vivo evaluations are imperative.

Orizon Research Institute of Odessa, Texas is the international distributor of ALKA V-6, which is currently being sold as a nutritional supplement on the company web site. The entire research study is also available on the Orizon Research web site at

SOURCE Orizon Research Institute

SOURCE Orizon Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
4. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
5. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
6. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
10. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
11. Newly Updated Pharmacy State Law Compendium Available
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):